Matt Henriksen

Yeah, well, it kind of sounds like, you know, those set it and forget it type of functions is that's the most beneficial for those who didn't really try to care about carb counting in the first place.

Yeah.

And, you know, moving then into the actual launch itself, you're up to nearly, if I'm correct, if I'm wrong, 30,000 islet users.

How has that launch been to get to that accelerated of a patient base?

And then, you know, the other thing too, just kind of thrown in there, and maybe I'm answering my own question here is the...

transition into using the pharmacy channel is something that you guys have highlighted a lot about.

And so maybe we can just start there.

And, you know, the different channels that these patients can get these durable insulin pumps and why switching into the pharmacy channel has been a benefit for

you know, it seems like for you, the patients and the payers.

Well, you know, it's interesting about the pay-as-you-go model, but it sounds like, you know, you're willing to... I mean, there's the opportunity cost of some of that upfront revenue for, you know, further payouts down the road.

What makes you feel comfortable about that model?

Yeah.

And then...

For the payers themselves, I mean, for them, they see some benefit of that as well because there's, I mean, maybe, how would I want to put this?

There's less risk involved of having to pay that upfront payment, right?

And so like that, when you see that $3,000 payment and then they switch,

the payers are eating that cost, right?

Very interesting.

And then, you know, kind of then going back to the patients that benefit from this.

I mean, we talked about in the, with the pivotal trial, how sicker patients benefited from it as much as kind of the, you know, patients that are, you know, more into the treatment beforehand.